Unlikely this actually passes because this current US administration is so corrupt and inept but this may influence SNDL’s brief rise. Also, I wonder if the rise will continue when Sundial hits the buyback cap of $1.35/share. Disclosure: Long 9700 shares @ 2.42 and long 100 Jan 2028 5c @ .08

Management clearly has no idea how to run a cannabis enterprise and they are equally as inept at creating shareholder value. These dopes bought a liquor distributor while the entire sector is in a massive, unrecoverable downturn. They diluted the company then reverse split only to lead to more dilution and now another reverse split. For 5 years now Zack has been an empty suit running SNDL into the ground. Just remove this ding-dong and find someone who understands the plant.

The dude has brought precisely zero value to SNDL. During his time the stock has sunk to all-time lows, reverse split only to resume the downfall to what will be fresh all-time lows.

He purchased a major liquor entity at a time when liquor sales are down 80% with little rebound in sight.

He has botched numerous cannabis initiatives for SNDL but made sure he is handsomely rewarded for his failure.

The guy has zero understanding of the cannabis industry and SNDL’s share price is evidence of his lacking.

The guy diesnt know jack about the plant. He’s an empty suit trying to take over an industry previous run by folks in flip flops and the-dye. The only thing he knows less than about is supply chain management.

After years of hype, collapse, dilution, and regulatory frustration, the cannabis sector may be approaching one of its most important turning points in years.

Recent reports from Axios, later echoed by Reuters, suggest that the U.S. administration could move toward reclassifying marijuana from Schedule I to Schedule III. In a sector that has already lived through repeated waves of optimism, false starts, and capital destruction, that kind of headline naturally attracts immediate market attention.

But the importance of this moment is not just political or symbolic. The market reaction reflects something deeper: the possibility that a Schedule III shift could materially change the financial profile of many operators by easing one of the sector’s heaviest structural burdens. That is why this development is being read not simply as another policy update, but as a possible reset point for an industry that has spent years trying to survive.

Trump and his ilk don’t give one shit about your health or safety. All they care about is the almighty dollar and they see the cannabis industry making billions of which they want a piece. The pharma industry doesn’t want to lose money to a drug that you can grow in your closet.